Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48

Benzinga · 2d ago
Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $48.